SLNO logo

Soleno Therapeutics (SLNO) Accounts receivable

Annual accounts receivable:

N/A
December 31, 2024

Summary

  • SLNO annual accounts receivable is not available.

Performance

1-year change

-

3-year change

-

5-year change

-

15-year change

-

SLNO Accounts receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Range

All-time high

$156.10K
SLNO annual accounts receivable is currently at an all-time high

3-year low

-
SLNO annual accounts receivable 3-year low is unknown

Earnings dates

Last annual earnings report date

Dec 31, 2024
SLNO previous annual earnings announcement was published on Dec 31, 2024

Next annual earnings report date

N/A
SLNO next annual earnings announcement has not yet been scheduled

OtherSLNObalance sheet metrics

annual accounts payable

$8.88M
SLNO annual accounts payable is $8.88 million

annual total assets

$330.97M
SLNO annual total assets is $330.97 million

annual total liabilities

$85.86M
SLNO annual total liabilities is $85.86 million

annual cash & cash equivalents

$87.93M
SLNO annual cash & cash equivalents is $87.93 million

Quarterly accounts receivable:

N/A
March 31, 2025

Summary

  • SLNO quarterly accounts receivable is not available.

Performance

3-month change

-

1-year change

-

3-year change

-

5-year change

-

SLNO Quarterly accounts receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Range

All-time high

$288.00K
SLNO quarterly accounts receivable is currently at an all-time high

3-year low

-
SLNO quarterly accounts receivable 3-year low is unknown

Earnings dates

Last quarterly earnings report date

Mar 31, 2025
SLNO previous earnings announcement was published on Mar 31, 2025

Next quarterly earnings report date

Aug 7, 2025
SLNO next earnings announcement is scheduled for Aug 7, 2025

OtherSLNObalance sheet metrics

quarterly accounts payable

$5.48M
SLNO quarterly accounts payable is $5.48 million

quarterly total assets

$318.09M
SLNO quarterly total assets is $318.09 million

quarterly total liabilities

$85.83M
SLNO quarterly total liabilities is $85.83 million

quarterly cash & cash equivalents

$81.33M
SLNO quarterly cash & cash equivalents is $81.33 million

Accounts receivable Formula

Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales

SLNO Accounts receivable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year--
3 y3 years--
5 y5 years--

SLNO Accounts receivable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year
5 y5-year
alltimeall time

SLNO Accounts receivable History

DateAnnualQuarterly
Sep 2017
-
$0.00(-100.0%)
Jun 2017
-
$3000.00(-97.3%)
Mar 2017
-
$110.00K(-19.7%)
Sep 2016
-
$137.00K(-52.4%)
Jun 2016
-
$288.00K(+54.0%)
Mar 2016
-
$187.00K(+19.8%)
Dec 2015
$156.10K
$156.10K(+66.1%)
DateAnnualQuarterly
Sep 2015
-
$94.00K(+683.3%)
Jun 2015
-
$12.00K(+50.0%)
Mar 2015
-
$8000.00(-78.4%)
Sep 2014
-
$37.00K(+103.3%)
Jun 2014
-
$18.20K(-55.8%)
Mar 2014
-
$41.20K(-72.5%)
Dec 2013
$149.60K(>+9900.0%)
$149.60K
Dec 2012
$0.00
-

FAQ

  • What is the all time high annual accounts receivable for Soleno Therapeutics?
  • What is the all time high quarterly accounts receivable for Soleno Therapeutics?

What is the all time high annual accounts receivable for Soleno Therapeutics?

Soleno Therapeutics all-time high annual accounts receivable is $156.10K

What is the all time high quarterly accounts receivable for Soleno Therapeutics?

Soleno Therapeutics all-time high quarterly accounts receivable is $288.00K
On this page